Ironwood Pharma Files to Begin China Phase III Trial of Linaclotide

Ironwood Pharmaceuticals has filed a Clinical Trial Application with the SFDA for a China Phase III trial of linaclotide. Linaclotide is a peptide agonist aimed at treating abdominal pain in patients with irritable bowel syndrome accompanied by constipation. Ironwood, a Massachusetts pharma, still owns the China rights to the drug, although it has partnered linaclotide for much of the rest of the world. More details.... Stock Symbol: (NSDQ: IRWD) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});